ylliX - Online Advertising Network
Company Ticker News

Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs

Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

In Frequency Therapeutics’ short lifetime as a company, it’s had its ups and downs. On Tuesday, during an R&D event day, the company unleashed a slew of announcements that add context to the development of a flagship hearing loss drug, and propose some directions.

...read full article on TechCrunch

ylliX - Online Advertising Network